9II.F BIOVICA INTL. SK-07

Healthcare Biotechnology Frankfurt Exchange
0.0199 EUR
Close of Nov 11, 2026
0.0002 0.0416
Market cap
EUR 7.47M
P/E
-
P/B
1.16x
ROE
-121.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jul 2026.

Is 9II.F undervalued?

Graham number

The Graham number of BIOVICA INTL. SK-07 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BIOVICA INTL. SK-07 fundamental analysis

No fundamental analysis for BIOVICA INTL. SK-07 yet.

BIOVICA INTL. SK-07 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BIOVICA INTL. SK-07

Biovica International AB (publ), a biotech company, develops and commercializes blood-based biomarker assays for oncologists monitor cancer progression in the European Union, the United States, and Asia. The company engages in the development of DiviTum TKa, a monitoring tool for patients with early or metastatic breast cancer undergoing treatment with CDK4/6 inhibitors. It serves cancer institutes and pharmaceutical companies. The company was incorporated in 2008 and is hea…

Full company profile